pdufa.bio
HomeConferences › ACR

ACR Convergence 2026

Updated ·next FDA decision on the calendar

Nov 6-11, 2026 · Orlando, US · Rheumatology.

DatesNov 6-11, 2026
LocationOrlando, US
Therapeutic focusRheumatology
Biotech presenters tracked0

Biotech presenters

Presenter list populates as abstracts are released.
Presenter history
We have tracked 13 biotech presentations by 13 companies across 2 past ACR meetings (2024-2025). Upcoming presenters populate as abstracts are released. See the conference run-up study for how these names behaved into the meeting.

How ACR stocks have traded historically

Median share-price move around a presentation, measured across 1425 all tracked conference presentations in our study (2017-2026), because our study holds fewer than 12 ACR events on their own.
30 days before-0.03%  50% rose · n=1425
10 days before+0.63%  52% rose · n=1425
Presentation day-0.56%  44% rose · n=1425
5 days after-1.59%  39% rose · n=1425
10 days after-1.93%  40% rose · n=1425
Read the whole row, not just the first line: across this study stocks have drifted up into these meetings and down out of them, and the effect is largest in the smallest companies. Medians are shown because a handful of large moves pulls an average away from the typical case. This is a historical distribution for a cohort of companies, not a forecast for any single company, and not investment advice. Methodology and the full study.

FAQ

When is ACR 2026?
ACR Convergence 2026 runs November 6-11, 2026 in Orlando, US. The date comes from the organiser's own announcement; check the organiser's site for the final programme.
Which biotech companies are presenting at ACR 2026?
None sourced yet. We list a company as presenting only when its own SEC filing or press release commits to this edition -- abstract titles and rumours don't qualify. The conferences page updates as filings land.
Why do medical conference dates matter for biotech stocks?
Trial results are often presented first at medical meetings, so a company's announced presentation is a dated, public catalyst. We publish a study of how biotech stocks have historically traded into conference presentations on the research page; it is historical measurement, not a prediction, and none of this is investment advice.